November 20, 2015 : Episode 1

Video

FDA Approvals for Daratumumab and Osimertinib, Regulatory Advances in RCC and CLL, and More

Related Videos
4 experts are featured in this series.
Sandip P. Patel, MD
4 experts are featured in this series.
Michael R. Bishop, MD
Mansi R. Shah, MD
Alec Watson, MD
Balazs Halmos, MD
Balazs Halmos, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Related Content
Subcutaneous Isatuximab Plus Pd in Multiple Myeloma | Image Credit: © LASZLO - stock.adobe.com
January 9th 2025

Subcutaneous Isatuximab Plus Pd Meets Coprimary End Points, Proves Noninferior to IV Administration in R/R Multiple Myeloma

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

NSCLC | Image Credit: © Axel Kock – stock.adobe.com
January 7th 2025

Amivantamab Plus Lazertinib Improves OS in EGFR-Mutant Advanced NSCLC

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

Multiple Myeloma | stock.adobe.com
January 6th 2025

Anito-Cel Demonstrates Safety and Early Efficacy in R/R Multiple Myeloma

This week’s top 5 includes a snapshot of FDA approvals from December, an exclusive roundup of critical NCCN guideline updates from 2024, and more.
January 4th 2025

The OncFive: Top Oncology Articles for the Week of 12/29